3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
672
Carcinoma, Non-Small-Cell Lung
461
Prostatic Neoplasms
390
Neoplasms
382
Lung Neoplasms
266
Multiple Myeloma
246
Colorectal Neoplasms
235
Neoplasm Metastasis
217
Melanoma
203
Ovarian Neoplasms
166
Leukemia, Myeloid, Acute
166
Pancreatic Neoplasms
155
Squamous Cell Carcinoma of Head and Neck
141
Carcinoma, Renal Cell
141
Lymphoma
137
Brain Neoplasms
132
Leukemia, Lymphocytic, Chronic, B-Cell
126
Glioblastoma
126
Recurrence
124
Lymphoma, Non-Hodgkin
123
Carcinoma, Hepatocellular
119
Head and Neck Neoplasms
115
Urinary Bladder Neoplasms
111
Triple Negative Breast Neoplasms
110
Stomach Neoplasms
110
Precursor Cell Lymphoblastic Leukemia-Lymphoma
105
Uterine Cervical Neoplasms
102
Hematologic Neoplasms
100
Lymphoma, Follicular
96
Sarcoma
95
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Anal Cancer Metastatic
×
1 year
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled